Anti-AKT1 (phospho S473) antibody
| Name | Anti-AKT1 (phospho S473) antibody |
|---|---|
| Supplier | Abcam |
| Catalog | ab8932 |
| Prices | $390.00 |
| Sizes | 100 µg |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Applications | ICC/IF ICC/IF IHC-P WB |
| Species Reactivities | Bovine, Human |
| Antigen | Synthetic peptide: CHFPQFSpYSAS conjugated to KLH, corresponding to C terminal amino acids 468-477 of Human AKT |
| Description | Rabbit Polyclonal |
| Gene | AKT1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
Normal breast tissue. Akt is weakly phosphorylated in normal tissue in the breast. The phosphorylated Akt is clearly localised in the cytoplasm.The phopho Ser 473 Akt antibody (ab8932) is used with no pretreatment at a dilution of 1:100 using Dako techmate streptavidin-biotin reagents.
Akt is phosphorylated on Ser 473 in breast tumor. The staining is much stronger than the weak basal level of phosphorylation in normal breast. The staining is cytoplasmic, as in normal tissue. The phopho Ser 473 Akt antibody (ab8932) is used with no pretreatment at a dilution of 1:100 using Dako techmate streptavidin-biotin reagents.This image is a magnification of the accompanying breast tumor image.
Confocal image of ab8932 at a 1:40 dilution staining cardiomyocytes infected with wild-type Akt in conjunction with a texas-red conjugated phalloidin to label filamentous actin in the cardiomyocytes.
Confocal image of ab8932 at a 1:40 dilution staining cardiomyocytes infected with wild-type Akt in conjunction with a texas-red conjugated phalloidin to label filamentous actin in the cardiomyocytes.
Immunohistochemical analysis of Human prostate cancer and melanoma cell lines, staining AKT1 (phospho S473) with ab8932.
Akt is phosphorylated on Ser 473 in breast tumor. The staining is much stronger than the weak basal level of phosphorylation in normal breast. The staining is cytoplasmic, as in normal tissue. The phopho Ser 473 Akt antibody (ab8932) is used with no pretreatment at a dilution of 1:100 using Dako techmate streptavidin-biotin reagents.
Product References
MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of - MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of
Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G, Luo J, Ren T. Mol Biol Cell. 2013 Jan;24(1):42-55.
A seven-marker signature and clinical outcome in malignant melanoma: a - A seven-marker signature and clinical outcome in malignant melanoma: a
Meyer S, Fuchs TJ, Bosserhoff AK, Hofstadter F, Pauer A, Roth V, Buhmann JM, Moll I, Anagnostou N, Brandner JM, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild PJ. PLoS One. 2012;7(6):e38222.
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and - Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and
Cima I, Schiess R, Wild P, Kaelin M, Schuffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3342-7. doi:
FSH-stimulated PTEN activity accounts for the lack of FSH mitogenic effect in - FSH-stimulated PTEN activity accounts for the lack of FSH mitogenic effect in
Dupont J, Musnier A, Decourtye J, Boulo T, Lecureuil C, Guillou H, Valet S, Fouchecourt S, Pitetti JL, Nef S, Reiter E, Crepieux P. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):271-6.
Increased activated Akt expression in renal cell carcinomas and prognosis. - Increased activated Akt expression in renal cell carcinomas and prognosis.
Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL, Kolbitsch C. J Cell Mol Med. 2009 Aug;13(8B):2181-8.
Short-Term culture of in vitro produced bovine preimplantation embryos with - Short-Term culture of in vitro produced bovine preimplantation embryos with
Jousan FD, Oliveira LJ, Hansen PJ. Mol Reprod Dev. 2008 Apr;75(4):681-8.
Epidermal growth factor receptor expression and activation in neuroendocrine - Epidermal growth factor receptor expression and activation in neuroendocrine
Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP, Caplin ME. J Neuroendocrinol. 2006 May;18(5):355-60.
Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour - Distinct transduction mechanisms of cyclooxygenase 2 gene activation in tumour
Volanti C, Hendrickx N, Van Lint J, Matroule JY, Agostinis P, Piette J. Oncogene. 2005 Apr 21;24(18):2981-91.